16-17 January 2015Crowne Plaza Barcelona Fira Center Barcelona, Spain

www.prIMEoncology.org/gyncongress2015

Progress and Controversies in Gynecologic Oncology Conference

2015

After successful completion of this educational activity, participants should be able to:

* Develop a practical approach to cervical cancer and vulvar cancer disease management

* Discuss the role of radiotherapy and systemic therapies in the management of endometrial cancer

* Derive the optimal management of ovarian cancer in the first-line setting based on disease stage and clinical presentation

* Assess standard and emerging therapeutic options for recurrent ovarian cancer and discuss their impact on patient outcomes

The 2015 Progress and Controversies in Gynecology Oncology Conference is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners including allied health professionals, involved in the management of gynecologic malignancies.

Welcome Venue

Who Should Attend

All inquiries related to the 2015 Progress and Controversies in Gynecologic Oncology Conference may be addressed to: gyncongress2015@prIMEoncology.org

Co-Chairs

Scientific CommitteeLearning Objectives

Nicoletta Colombo, MD University of Milan-Bicocca Milan, Italy

Stanley B. Kaye, MD The Royal Marsden Hospital Sutton, United Kingdom

Andreas du Bois, MD, PhD Klinikum Essen Mitte Essen, Germany

Bradley J. Monk, MD, FACS, FACOG Creighton University School of Medicine at St Joseph’s Hospital and Medical Center Phoenix, Arizona, United States

Andrés Poveda, MD Fundación Instituto Valenciano de Oncología Valencia, Spain

Eric Pujade-Lauraine, MD, PhD Centre Hospitalier Universitaire Hôtel-Dieu Paris, France

Ignace Vergote, MD, PhD University Hospital Gasthuisberg Leuven, Belgium

Crowne Plaza Barcelona Fira CenterAvda Rius I Taulet, 1-3Barcelona, Spain

On behalf of the Co-Chairs and Scientific Committee, we are pleased to invite you to the 2015 Progress and Controversies in Gynecologic Oncology Conference, to be held in Barcelona, Spain, on 16-17 January 2015. This meeting will serve as a valuable forum for the presentation and discussion of newly available data across various gynecologic malignancies including ovarian, cervical, and endometrial cancers. Participants will be provided with updates on practice-changing data in a practical and interactive format, fostering discussion, and impacting clinical outcomes for patients.

Continuing education

Provider

An application has been made to the EACCME® for CME Accreditation of this event.

This educational activity is provided by prIME Oncology.

RegistrationFaculty

Registration fees include VAT.*Supporting documentation of eligibility may be required.

Registration DeadlinesEarly registration rate: 1 November 2014 (23.59 CET)Regular registration rate: 28 November 2014 (23.59 CET)

To RegisterYou may register online through 12 January 2015 at www.prIMEoncology.org/gyncongress2015. Registration confirmations will be issued upon successful completion of registration and reminders will be issued before the meeting. To preregister, registration and payment must be received no later than 1 November 2014 (early registration rate) or 28 November 2014 (regular registration rate). Please register onsite after 12 January 2015.

Group RegistrationsGroup registration will be accepted. For more information, please contact:registrations.gyn2015@prIMEoncology.org

CancellationTo receive a refund of registration fees, written notice of cancellation must be received at registrations.gyn2015@prIMEoncology.org

The following deadlines and cancellation fee schedule will apply:* Before 1 November 2014: € 50,- administrative charge * From 1 November 2014: 60% cancellation fee applies on registration fee(s) * From 29 November 2014: 100% cancellation fee applies on registration fee(s)* Name changes from 29 November 2014: € 15,-fee is charged per change

Any registration fees remitted will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 28 November 2014. prIME Oncology does not accept responsibility for reimbursement of travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice

Early Regular Late/Onsite

Physician € 375,- € 475,- € 575,-

Nurse € 225,- € 300,- € 350,- Fellow/Resident/Student* € 225,- € 300,- € 350,-

Industry/Society/Press € 425,- € 525,- € 625,-

Registration Fees

Complete congress information and registration available at:www.prIMEoncology.org/gyncongress2015

Accommodation

A limited number of rooms are available at the Crowne Plaza Barcelona Fira Center (meeting venue). Delegates are recommended to make their hotel reservation as early as possible. You can book your hotel room with the online registration form at the registration tab at www.prIMEoncology.org/gyncongress2015 or send an email to registrations.gyn@prIMEoncology.org.

Frédéric Amant, MD, PhDCatholic UniversityLeuven, Belgium

Michael Birrer, MD, PhDMassachusetts General Hospital Boston, Massachusetts, United States

Anna Fagotti, MD, PhDCatholic University of the Sacred HeartRome, Italy

Philipp Harter, MDKlinikum Essen MitteEssen, Germany

Felix Hilpert, MD, DMSciChristian-Albrechts-University of KielKiel, Germany

Sven Mahner, MD, PhDUniversity Medical Center Hamburg-EppendorfHamburg, Germany

Mansoor Mirza, MDRigshospitaletCopenhagen, Denmark

Philippe Morice, MDInstitute Gustave RoussyVillejuif, France

Jan Persson, MD, PhDLund UniversityLund, Sweden

Jaime Prat, MD, PhD, FRCPathHospital de la Santa Creu i Sant PauBarcelona, Spain

Alexandra Taylor, MBBS, MDThe Royal Marsden HospitalLondon, United Kingdom

Vincent Vandecaveye, MD, PhDUniversity of LeuvenLeuven, Belgium

Friday, 16 January 2015

13.00 Welcome and introduction

Session I Cervical Cancer and Vulvar Cancer 13.10 Current status of treatment for vulvar cancer Sven Mahner, MD, PhD

13.40 Technical innovations in robotic surgery Jan Persson, MD, PhD

14.10 Update on neoadjuvant chemotherapy in cervical cancer Nicoletta Colombo, MD

14.40 Update on targeted therapy and immunotherapy for cervical cancer Bradley J. Monk, MD, FACS, FACOG

15.10 Break

Session II Endometrial Cancer and Beyond 15.40 Debate: Role of radiotherapy in grade 3 FIGO IB endometrial cancer Pro Radiotherapy: Alexandra Taylor, MBBS, MD Contra Radiotherapy: Mansoor Mirza, MD

16.30 Treatment of recurrent endometrial cancer and evaluation of new agents Andrés Poveda, MD 17.00 What are the oncologic risks of morcellation of the uterus? Frédéric Amant, MD, PhD 17.30 Concluding remarks: Day 1

17.35 Adjourn

18.15 - Industry-supported satellite symposium19.30

Agenda

Saturday, 17 January 2015

8.30 Welcome and introduction Session III Ovarian Neoplasm I: Emerging Concepts 8.35 The impact of molecular testing on therapeutic decisions in ovarian cancer Michael Birrer, MD, PhD

9.05 Evolving role of upfront and postoperative imaging in ovarian cancer Vincent Vandecaveye, MD, PhD

9.35 Future of targeted agents and combinations in ovarian cancer Stanley B. Kaye, MD

10.05 Break

Session IV Ovarian Neoplasm II: Practical Applications in the First-Line Setting 10.40 Personalized medicine: Identification and treatment of fragile patients Felix Hilpert, MD, DMSci

11.10 Debate: HIPEC plays a role in treatment of advanced ovarian cancer Pro: Anna Fagotti, MD, PhD; Contra: Philipp Harter, MD

11.50 Break

12.15- Industry-supported satellite symposium13.30

Session V Borderline Ovarian Tumors

13.45 Pathologist’s view on the current status of borderline tumors Jaime Prat, MD, PhD, FRCPath

14.15 Clinical aspects: Fertility-sparing surgery of borderline ovarian tumors Philippe Morice, MD 14.45 Break

Session VI Ovarian Neoplasm III: Recurrence

15.00 Interactive Clinical Case: Platinum-resistant disease Ignace Vergote, MD, PhD

15.30 Interactive Clinical Case: Platinum-sensitive disease Andreas du Bois, MD, PhD

16.00 Ovarian cancer patients who have received multiple prior therapies: When to stop or continue treatment? Eric Pujade-Lauraine, MD, PhD 16.30 Concluding remarks: Day 2

16.45 Adjourn

Agenda

EU OfficeprIME OncologySchenkkade 50, Suite 162595 AR The Haguethe Netherlands

©2015 prIME Oncology

Additional information and registration available at:

www.prIMEoncology.org/gyncongress2015

Support

This educational activity is supported by AstraZeneca and F. Hoffmann-La Roche Ltd.

* Friday’s satellite symposium is supported by AstraZeneca* Saturday’s satellite symposium is supported by F. Hoffmann-La Roche Ltd